Drug Trial Radar · NCT00286897
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Last checked: Nov 19, 2026Latest source record: Nov 3, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
702
Actual
Start
Feb 2006
Primary completion
Jun 2007
Study completion Aug 2007
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Feb 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications. During the first 8 weeks, the patient's levodopa doses may be adjusted if necessary by the investigator. For the remainder of the 22 weeks, all medications should be kept stable. Patients will be required to attend the clinic twice during the screening period and then a further 8 times during the treatment period. They will be required to complete home diaries where they will record their motor function. In addition, their doctor will assess their Parkinson's disease during the clinic visits. There will also be blood draws for safety and pharmacokinetic and pharmacogenomics evaluation. Following the treatment and assessment period, they will return to the clinic one month later for follow up.
Conditions
- Parkinson's Disease
Interventions
E2007Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient diaries: Change from baseline to final efficacy visit in the mean total daily OFF time (hr).
Locations
118 sites in 17 countries. Site status is shown where the registry gives one.
University Clinic Innsbruck
Innsbruck, Austria
Department of Neurology
Vienna, Austria
Cliniques Universitaires St-Luc
Brussels, Belgium
C.H.U.de Charleroi
Charleroi, Belgium
U.Z. Antwerpen
Edegem, Belgium
U.Z. Gent
Ghent, Belgium
C.H.R. de la Citadelle
Liège, Belgium
Hopital St-Pierre
Ottignies, Belgium
St-Andries Ziekenhuis
Tielt, Belgium
University Hospital
Olomouc, Czechia
University Hospital
Ostrava, Czechia
Pliklinika Modry Pavilon
Ostrava, Czechia
Nemocnice Pardubice
Pardubice, Czechia
FN Plzen
Pilsen, Czechia
Nemocnice Pisek
Plsek, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
VFN Praha
Prague, Czechia
Parnu Hospital
Pärnu, Estonia
West Tallinn Central Hospital
Tallinn, Estonia
Tartu University Hospital
Tartu, Estonia
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, France
Service Neurologie
Bayonne, France
CHU Gabrief Montpied
Clermont-Ferrand, France
Contis, Patrick
Colomiers, France
Site not named
Lille, France
Centre de Pharmacologie Clinique et Evaluation Therapeutique
Marseille, France
Site not named
Nantes, France
Hopital de la Pitie Salpetriere
Paris, France
Centre d'Investigation Clinique, Hospital Purpan
Toulouse, France
Kliniken Beelitz GmbH
Beelitz-Heilstätten, Germany
Uni-klinikum Charite, Campus Virchow-klinikum
Berlin, Germany
Site not named
Bochum, Germany
Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
Neurologische Universitatsklinik
Göttingen, Germany
Universitatkrankenhaus Hamburg Eppendorf
Hamburg, Germany
Site not named
Hanau, Germany
Site not named
Hanover, Germany
Paracelsus-Elena-Klinik
Kassel, Germany
Gertrudis-Klinik, Parkinson Klinik
Leun-Biskirchen, Germany
Universitatsklinik Lubeck Klinik fur Neurologie Ratzeburger Allee 160 D-23538 Lubeck
Lübeck, Germany
Showing 40 of 118 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.